Latest Conference Articles

January 30th 2022, 11:00am

SGO Winter Meeting

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

January 28th 2022, 10:07pm

SGO Winter Meeting

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

January 28th 2022, 9:28pm

SGO Winter Meeting

Yovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.

January 28th 2022, 6:40pm

SGO Winter Meeting

Yovanni Casablanca, MD, discusses the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

January 27th 2022, 10:20pm

SGO Winter Meeting

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

January 23rd 2022, 11:00am

Gastrointestinal Cancers Symposium (ASCO GI)

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

January 23rd 2022, 12:05am

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

January 22nd 2022, 8:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

January 22nd 2022, 7:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

January 22nd 2022, 6:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

January 22nd 2022, 6:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

January 22nd 2022, 5:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

January 22nd 2022, 5:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

January 22nd 2022, 3:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

January 22nd 2022, 3:54pm

Gastrointestinal Cancers Symposium (ASCO GI)

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

January 22nd 2022, 3:50pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

January 21st 2022, 10:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

January 21st 2022, 10:47pm

Gastrointestinal Cancers Symposium (ASCO GI)

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.

January 21st 2022, 10:46pm

Gastrointestinal Cancers Symposium (ASCO GI)

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.

January 21st 2022, 9:44pm

Gastrointestinal Cancers Symposium (ASCO GI)

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.